Short Interest in Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Rises By 52.4%

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 271,800 shares, anincreaseof52.4% from the July 31st total of 178,300 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 2,718.0 days. Based on an average trading volume of 100 shares, the short-interest ratio is presently 2,718.0 days.

Swedish Orphan Biovitrum Stock Performance

Shares of OTCMKTS:BIOVF opened at $29.18 on Monday. The company has a market cap of $10.39 billion, a price-to-earnings ratio of 24.52 and a beta of 0.45. The company has a 50-day moving average price of $29.66 and a 200-day moving average price of $29.50. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 0.22. Swedish Orphan Biovitrum has a 12 month low of $25.80 and a 12 month high of $32.25.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.18 by $0.06. The firm had revenue of $649.61 million during the quarter, compared to the consensus estimate of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.